ACR Promotes New COVID-19 Vaccine Clinical Guidance for Rheumatic Patients

Save

The American College of Rheumatology has published a draft guidance on the use of COVID-19 vaccination in rheumatic disease and musculoskeletal disease patients, based on the efforts of the North American Task force. The document provides guidance to rheumatology providers on the use of the COVID-19 vaccine and the associated management of RMD patients around the time of vaccination. Here is a summary of the recommendations.

Comorbidity and Drugs Drive COVID-19 Severity and Survival in Rheumatic Disease

Save

While comorbidities are associated with severe COVID-19 infection, it appears they also influence severity and survival in rheumatic disease (RMD), according to a a French cohort study,

RheumNow Podcast – Rheumatology Burnout (1.29.2021)

Save

Dr. Jack Cush reviews this past week's journal articles and news features on RheumNow.com. Colchicine, vaccine rollout, risk of RA in endometriosis patients, tREACH trial, lupus nephritis news, rheumatology burnout and more.

High Placebo Responses in SLE Trials

Save

A systematic review by Urowitz and colleagues examined placebo responses in randomized controlled trials of non-renal, non-neuropsychiatric SLE patients showing unexpectedly high placebo responses; with more than one-third of the placebo-treated SLE patients responding by validated outcome measures.

Lupus Nephritis Despite Low Level Proteinuria

Save

Kidney International reports on a series of systemic lupus erythematosus (SLE) patients, who despite inactive urinary sediment and low level proteinuria, had a high rate of glomerulonephritis (GN) proven by renal biopsy; moreover, the LN was not predicted by laboratory abnormalities.

Is there such a thing as "Preclinical Lupus" - half to 2/3 of SLE pts had + serologies up to 9 yrs before the Dx @KDAO2011 @UTSWIMchief @UTSWIMchief https://t.co/ThpKjZEG2v